The secondary efficacy measurements were the response and remission rates , the Clinical Global Impression - Improvement of Illness ( CGI-I ) score at the end of the study , and the change of the HAMD-14 total score and quality of sleep [ evaluated by the Pittsburgh Sleep Quality Index ( PSQI ) scale ] during the study period .